Pharma / Biotech

Keytruda Approved for Recurrent or Metastatic Cutaneous Squamous Cell Cancer

The FDA approved pembrolizumab (Keytruda, Merck) for patients with recurrent or metastatic cutaneous squamous cell carcinoma (cSCC) that is not curable by surgery or radiation. 

Source link

Related posts

PHENTERMINE HYDROCHLORIDE Capsule [Bryant Ranch Prepack]


clinical pharmacology; +200 new citations


SODIUM SULFACETAMIDE Liquid [BioComp Pharma, Inc.]


This website uses cookies to improve your experience. We'll assume you're ok with this, but you can opt-out if you wish. Accept Read More

Privacy & Cookies Policy


COVID-19 (Coronavirus) is a new illness that is having a major effect on all businesses globally LIVE COVID-19 STATISTICS FOR World